Virus-based immunotherapy biotech Transgene is to begin clinical trials of its head and neck cancer drug candidate TG4050 after gaining regulatory clearance from the UK regulator. Transgene focuses on developing virus-based immunotherapies for sol...
Original Article: Transgene begins trials of head and neck cancer vaccine